P
Payal Kapur
Researcher at University of Texas Southwestern Medical Center
Publications - 244
Citations - 11224
Payal Kapur is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Clear cell renal cell carcinoma & Cancer. The author has an hindex of 42, co-authored 223 publications receiving 8743 citations. Previous affiliations of Payal Kapur include University of Texas at Dallas & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers.
Payal Kapur,Yair Lotan,Ellen S King,Wareef Kabbani,Anirban P. Mitra,Ahmed Mosbah,Hassan Abol-Enein,Mohamed A. Ghoneim,Ramy F. Youssef,Ramy F. Youssef +9 more
TL;DR: In this paper, the authors assessed the association between biologic markers and clinicopathologic characteristics in a cohort of 21 patients with primary urinary bladder adenocarcinoma and found that the best prognostic combination of markers was combined alterations in p27 and Ki-67 and was associated with stage (P =.012), grade (P <.005), DNA ploidy, and lymph node involvement.
Journal ArticleDOI
What is the role of nephrectomy following complete response to checkpoint inhibitors
TL;DR: A 65-year old man experienced 6 months of gradually worsening fatigue, weight loss, and dyspnea prompting evaluation with a chest x-ray demonstrating pulmonary nodules in the right lung and a “white out” of his left lung.
Journal ArticleDOI
Correlating Anticancer Drug Delivery Efficiency with Vascular Permeability of Renal Clearable Versus Non-renal Clearable Nanocarriers.
TL;DR: In this paper, a head-to-head comparison between 5 nm renal clearable and 30 nm non-renal clearable gold nanoparticle (AuNP)-based drug delivery systems (DDSs) in the delivery of doxorubicin (DOX) was conducted.
Journal ArticleDOI
Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non–muscle-invasive high-grade bladder cancer
Niccolo Passoni,Bishoy A. Gayed,Payal Kapur,Arthur I. Sagalowsky,Shahrokh F. Shariat,Yair Lotan +5 more
TL;DR: Markers were not significant predictors of recurrence nor progression in patients with high-grade NMIBC and their addition to prediction models is of little benefit.
Journal ArticleDOI
PBRM1 loss is a late event during the development of cholangiocarcinoma.
Claudio Luchini,Scott A. Robertson,Seung-Mo Hong,Matthäus Felsenstein,Robert A. Anders,Antonio Pea,Alessia Nottegar,Nicola Veronese,Jin He,Matthew J. Weiss,Paola Capelli,Aldo Scarpa,Pedram Argani,Payal Kapur,Laura D. Wood +14 more
TL;DR: The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis, which encodes a subunit of the SWI/SNF complex.